Ontology for Symptomatic Treatment of Multiple Sclerosis
Abstract Objectives: Symptomatic treatment is an essential component in the overall treatment of multiple sclerosis (MS). However, knowledge in this…
Abstract Objectives: Symptomatic treatment is an essential component in the overall treatment of multiple sclerosis (MS). However, knowledge in this…
Abstract Background: Patients with multiple sclerosis (MS) often undergo complex treatment regimens, resulting in an increased risk of polypharmacy and…
Abstract Background: Multiple sclerosis (MS) is the most common immune-mediated demyelinating disease in younger adults. Patients with MS (PwMS) are…
Abstract Therapeutic drug monitoring of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) is based on a complex procedure and is therefore not…
Abstract Background and purpose: Nabiximols is a therapeutic option for patients with multiple sclerosis (MS) spasticity whose symptoms are poorly…
Abstract Historically, Cannabis is one of the first plants to be domesticated and used in medicine, though only in the…
Abstract Palmitoylethanolamide (PEA) stands out among endogenous lipid mediators for its neuroprotective, anti-inflammatory, and analgesic functions. PEA belonging to the…
Abstract Simple Summary: Neurodegenerative diseases represent an important cause of morbidity and mortality worldwide. Existing therapeutic options are limited and…
Abstract The innate immune response to bacterial and viral molecules involves the coordinated production of cytokines, chemokines, and type I…
Abstract In patients with multiple sclerosis (MS), a typical pattern of muscle tone alteration, known as spasticity, is frequently observed…